Abstract
Gliflozins, in addition to proving to be effective in the treatment of type 2 diabetes mellitus (T2DM), have been demonstrating significant improvements in cases of heart failure (HF) and chronic kidney disease (CKD). However, the reported clinical benefits for gliflozins cannot be explained solely by SGLT2 inhibition in the proximal renal tubule. In this project, we intend to isolate and…